Elekta AB (publ) - Asset Resilience Ratio
Elekta AB (publ) (EKTA-B) has an Asset Resilience Ratio of 9.18% as of January 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See EKTA-B working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2012–2025)
This chart shows how Elekta AB (publ)'s Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Elekta AB (publ) total assets.
Liquid Assets Composition Over Time
This chart breaks down Elekta AB (publ)'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore how much of Elekta AB (publ)'s assets are long-term investments to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr2.54 Billion | 9.18% |
| Short-term Investments | Skr0.00 | 0% |
| Total Liquid Assets | Skr2.54 Billion | 9.18% |
Asset Resilience Insights
- Limited Liquidity: Elekta AB (publ) maintains only 9.18% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Elekta AB (publ) Industry Peers by Asset Resilience Ratio
Compare Elekta AB (publ)'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
TransMedics Group Inc
NASDAQ:TMDX |
Medical Devices | 0.00% |
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223 |
Medical Devices | 0.84% |
|
Novocure Ltd
NASDAQ:NVCR |
Medical Devices | 43.72% |
|
Shenzhen New Industries Biomedical
SHE:300832 |
Medical Devices | 9.95% |
|
Jafron Biomedical Co Ltd
SHE:300529 |
Medical Devices | 34.37% |
|
Hangzhou AGS MedTech Co. Ltd. A
SHG:688581 |
Medical Devices | 18.80% |
|
Nanjing Vishee Medical Technology Co Ltd
SHG:688580 |
Medical Devices | 10.74% |
|
Nanjing Medlander Medical Technology Co. Ltd. A
SHG:688273 |
Medical Devices | 34.29% |
Annual Asset Resilience Ratio for Elekta AB (publ) (2012–2025)
The table below shows the annual Asset Resilience Ratio data for Elekta AB (publ).
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-04-30 | 10.20% | Skr2.96 Billion ≈ $318.01 Million |
Skr28.98 Billion ≈ $3.12 Billion |
+3.24pp |
| 2024-04-30 | 6.96% | Skr2.19 Billion ≈ $235.14 Million |
Skr31.41 Billion ≈ $3.38 Billion |
-0.64pp |
| 2023-04-30 | 7.60% | Skr2.25 Billion ≈ $242.14 Million |
Skr29.61 Billion ≈ $3.19 Billion |
-4.10pp |
| 2022-04-30 | 11.70% | Skr3.08 Billion ≈ $331.13 Million |
Skr26.30 Billion ≈ $2.83 Billion |
-1.07pp |
| 2021-04-30 | 12.77% | Skr3.17 Billion ≈ $341.36 Million |
Skr24.84 Billion ≈ $2.67 Billion |
-5.63pp |
| 2020-04-30 | 18.40% | Skr5.23 Billion ≈ $562.62 Million |
Skr28.41 Billion ≈ $3.06 Billion |
+8.42pp |
| 2019-04-30 | 9.98% | Skr2.40 Billion ≈ $258.49 Million |
Skr24.06 Billion ≈ $2.59 Billion |
+1.81pp |
| 2018-04-30 | 8.17% | Skr1.83 Billion ≈ $197.37 Million |
Skr22.46 Billion ≈ $2.42 Billion |
+2.09pp |
| 2017-04-30 | 6.08% | Skr1.27 Billion ≈ $137.00 Million |
Skr20.95 Billion ≈ $2.25 Billion |
+7.87pp |
| 2016-04-30 | -1.80% | Skr-349.00 Million ≈ $-37.56 Million |
Skr19.44 Billion ≈ $2.09 Billion |
-0.12pp |
| 2015-04-30 | -1.67% | Skr-354.00 Million ≈ $-38.10 Million |
Skr21.18 Billion ≈ $2.28 Billion |
-45.02pp |
| 2012-04-30 | 43.35% | Skr6.60 Billion ≈ $710.70 Million |
Skr15.23 Billion ≈ $1.64 Billion |
-- |
About Elekta AB (publ)
Elekta AB (publ), a medical technology company, provides clinical solutions for treating cancer and brain disorders in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers linear accelerator and radiation therapy products comprising Elekta Unity for anatomy-specific MR imaging; Elekta Evo that delivers offline and online adaptive radiation therapy; Elekta Versa … Read more